ocriplasmin

Research offers insights to success in macular hole surgery
Research offers insights to success in macular hole surgeryMacular hole surgery can be performed using various techniques and technologies. According to John T. Thompson, MD, the available evidence supports always incorporating internal limiting membrane (ILM) peeling, staining of the ILM, and having a large gas bubble in the eye on the first postoperative day.
Idiopathic macular holes: When to perform vitrectomyRetina specialists and comprehensive ophthalmologists should identify full thickness macula holes and, generally, recommend a vitrectomy to close them and improve vision.
Integrin peptide yields positive outcomes for VMA, VMT in phase II trialA new possible therapy for vitreomacular adhesion and vitreomacular traction had positive results in a phase II trial.
Patient-reported vision improved by ocriplasminPatients with symptomatic vitreomacular adhesion (VMA) find that a single intravitreal injection of ocriplasmin improves their vision, according to an ancillary analysis of two multicentre randomised clinical trials reported in JAMA Opthalmology.
Ocriplasmin success based on proper patient selectionReal-world experience with ocriplasmin indicates it is an effective, safe, and cost-effective treatment for symptomatic vitreomacular adhesion in properly selected eyes.
Ocriplasmin an option for FTMH and vitreomacular adhesionOcriplasmin (Jetrea, ThromboGenics) is an option for the management of patients who have full-thickness macular hole (FTMH) and vitreomacular adhesion, according to an article in press in the American Journal of Ophthalmology.
Ocriplasmin outcomes favorable in post-marketing experienceData reported by American surgeons using ocriplasmin for treatment of symptomatic vitreomacular adhesion (VMA) show that it is possible to increase the success rate through careful patient selection, said David Chow, MD.
Ocriplasmin in exudative AMD: Safety and efficacy resultsOcriplasmin achieved complete resolution of vitreomacular adhesion (VMA) in more study patients with VMA and exudative age-related macular degeneration compared with patients in the sham group.
Appropriate case selection maximizes success with ocriplasminResults from the MIVI-TRUST trials serve as a guide to identifying cases of symptomatic vitreomacular adhesion that are most likely to achieve success with ocriplasmin treatment.
New system classifies vitreomacular disease, provides common languageAn international panel of ophthalmologists have developed a classification system of vitreomacular diseases, with the goals of objectivity based on optical coherence tomography (OCT) findings and ease of use.